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Molecular characterization of non-small cell lung cancer 
(NSCLC) and implications for treatment and prognosis 
are increasingly important. Selection of molecularly 
targeted systemic therapy is commonly based on clonal 
oncogenic drivers of which epidermal growth factor 
receptor (EGFR)  and the fusion gene echinoderm 
microtubule-associated protein-like 4 anaplastic lymphoma 
kinase (EMLA4-ALK) are examples established in clinical 
practice. The former, found in approximately 10–15% 
of patients with NSCLC in the western world, is more 
prevalent in adenocarcinoma, non/light smokers, younger 
females, and patients of far eastern descent (1). Patients 
with EMLA4-ALK translocated tumors share similar 
clinical characteristics but are less prevalent (2). Several 
other rarer candidate driver mutations, including ROS 
proto-oncogene 1, receptor tyrosine kinase (ROS-1), are 
also implicated in NSCLC (3).
Crizotinib, a multi-targeted tyrosine kinase inhibitor, was 
initially awarded accelerated approval from the US Food 
and Drug Administration (FDA) in ALK driven pre-treated 
NSCLC in 2011. Approval was based on early phase studies 
(2,4) later supported by confirmatory phase 3 studies (5) 
and subsequently expanded to patients who were treatment 
naïve (6). Further generations of ALK inhibitors have since 
been developed with the aim of overcoming inevitable 
treatment failure due to tumor cell resistance (7,8). 
ROS-1, a less frequent genomic event in NSCLC, is 
thought to be homologous with ALK. In patients who 
harbor this translocation response rates to crizotinib are 
70–80% (9,10), which led to its FDA approval for this 
indication in 2016. Although crizotinib demonstrates 
excellent initial response rates in both these select 
groups, cancer progression is an almost certain event. 
Understanding the associated resistance mechanisms can 
help with next generation drug design to overcome these 
therapy resistant molecular changes. A clinically approved 
example of this approach is osimertinib, a tyrosine kinase 
inhibitor, which was developed to overcome treatment 
failure by targeting the EGFR resistance mutation T790M. 
In the Journal of Thoracic Oncology, Dziadziuszko 
et al. report the identification of a novel resistance 
mechanism in NSCLC harboring a ROS-1 translocation 
both in preclinical models and a patient data set. They 
initially describe a young smoking female patient with a 
ROS-1 translocated lung adenocarcinoma, who was treated 
with crizotinib. The tumor developed drug resistance 
at 15 months. ROS-1 break-apart fluorescence in situ 
hybridization (FISH) analysis and DNA sequencing showed 
no evidence of gain or loss of ROS-1 gene fusion copy 
number when comparing pre- and post-crizotinib tumor 
samples. Further molecular testing however revealed 
the development of a KIT gene mutation (p.D816G) in 
the crizotinib treated specimen. The authors examined 
three further patients, however two of these did not have 
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sufficient tissue for analysis and the third was shown not 
to harbor any KIT mutations. Despite the limited clinical 
data describing the same mutation, in vitro studies support 
the hypothesis that the KIT (p.D816G) mutation is part 
of a resistance pathway in crizotinib treated NSCLC cell 
lines. Furthermore, it was observed that crizotinib led to 
gradual loss of inhibition of ERK1/2, likely provoked by 
the emergence of the KIT mutation later overcome by 
ponatinib, an inhibitor of KIT (11). 
Acquired drug resistance to targeted therapy is a 
common problem in advanced NSCLC. It largely takes 
two forms: first the development of further mutations in 
the target receptor rendering ineffective interaction with 
the originally effective drug, or second, the development 
of compensatory cross talk between intracellular pathways, 
overcoming the drug effects. A change in phenotype 
to small cell lung cancer, epithelial-to-mesenchymal 
transition, and immune evasion are also thought to play 
a role (12). In addition unselected therapies, such as 
chemotherapy, exert treatment pressure on cancers and 
may influence the molecular profile of emergent resistant 
clones (13). 
It is well documented in ALK mutated lung cancer that 
resistance mutations develop within the tyrosine kinase 
domain, for example L1196M and C1156Y, following 
treatment with crizotinib (14). Although the development 
of second generation ALK inhibitors were designed to 
overcome crizotinib induced resistance mutations, studies 
have shown that their use promotes further mutations both 
within the tyrosine kinase domain and as separate oncogenic 
drivers (12,15).
Ceritinib, an inhibitor of ALK, is now used for patients 
with cancer progression post crizotinib (16). Encouragingly, 
it has also been shown to exhibit activity against ROS-1 
driven disease, however this requires further clinical 
validation (17). Alectinib, an inhibitor of both ALK and 
the proto-oncogene RET, initially designed to overcome 
crizotinib resistance, has recently demonstrated superiority 
in treatment naïve patients compared to crizotinib, 
although its activity in ROS-1 driven disease remains 
uncertain (18). Similarly, ROS-1 is associated with acquired 
missense mutations, such as G2032R and D2033N within 
the kinase domain, following treatment with crizotinib 
(19,20). Drugs such as cabozantinib are under investigation 
to overcome intrinsic mutations within ROS-1 (21). 
The reprogramming of signaling pathways through 
other molecules is well established (including activation 
of EGFR (12), RAS (22) and now the above described 
KIT mutation) playing a significant role in clinical drug 
resistance. Interestingly, KIT (p.D816G) is also a recognized 
resistance mutation in gastrointestinal stromal tumors 
(GIST) following treatment with imatinib, an inhibitor of 
KIT. Although the exact mechanism of resistance appears 
different in GIST tumors (23), KIT mutations in ALK 
translocated NSCLC have been shown to be managed with 
simultaneous crizotinib and imatinib treatment reversing its 
resistant phenotype in cell lines (24).
The ROS-1 tyrosine kinase receptor is thought to 
act through more than one intracellular pathway as 
downstream signaling through PI3K/AKT and MAPK 
are both recognized. The tyrosine protein kinase KIT 
shares similar signaling pathways following provocation 
with its natural ligand stem cell factor. The hypothesis 
that downregulation of these pathways through ROS-1 
inhibition may lead to compensatory upregulation through 
the activation of KIT could conceivably lead to drug failure. 
Dual inhibition of ROS-1 and KIT could be explored to 
overcome the resistance pathway to crizotinib. This strategy 
of drug combination therapy is supported by the authors as 
ROS-1 and KIT can be constitutively active at the same 
time or ROS-1 activates KIT, through its inhibition. 
This approach seems worth evaluating as manipulation 
of neighboring pathways has been successful in MET 
amplified EGFR mutant NSCLC (25). 
Emerging mechanisms of resistance in EGFR mutant 
lung cancer are now being tackled in the clinic. As described 
earlier, osimertinib, the first licensed tyrosine kinase 
inhibitor for this indication, targets the frequently identified 
T790M gatekeeper mutation within the EGFR tyrosine 
kinase domain. Particularly interesting is the superior 
efficacy of osimertinib over early generation primary 
inhibitors in patients who have never encountered EGFR 
inhibition. Recently, published studies have confirmed 
superiority in median progression free survival (PFS) and 
overall response rates (ORR) compared with standard of 
care treatment. At best, PFS was measured at 22.1 months 
and ORR almost 90%. Notably, it was shown that patients 
who developed progression in cancer in one of the studies 
demonstrated resistance pathways which did not include 
T790M (26,27).
Further work is  st i l l  needed to develop robust 
methods of managing tumor resistance. Targeting these 
pathways may not always lead to reversing drug failure, as 
demonstrated by the authors. Variation in KIT behavior to 
inhibition with ponatinib was noted, indicating that certain 
cellular characteristics may dictate how KIT responds to 
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pharmacological suppression. In the absence of stromal 
tissue, an immune system and cellular heterogeneity, 
assessment of these mechanisms is more challenging and 
better tumor models are desperately needed to increase our 
understanding of why tumors behave in this way.
Complicating matters further, it is also important 
to consider both the temporal evolution and spatial 
heterogeneity of lung cancer (28). The increasing 
complexity of mapping a cancer’s evolution through space 
and time requires repeated molecular characterization 
of new sites of disease to best understand the emerging 
mechanisms of resistance and tailor therapy for our patients. 
A personalized approach to cancer management remains an 
ethos commonly shared amongst cancer treating physicians, 
and this evidence provides further support for individualized 
molecular treatment against emerging validated targets. 
Future clinical trials concentrating on disease resistance 
to primary treatment, not just in NSCLC, remain hugely 
important. 
Given its low prevalence and despite enthusiastic 
attempts to locate these patients, research into ROS-1 
mutations may be guided by ALK driven disease due to 
their shared homology. Current credible approaches to 
overcome treatment failure include deeper inhibition of 
ROS-1 and exploring the sequencing of targeted therapy 
tackling by-pass resistance mutations when they emerge. 
The balance of combination therapy and associated 
toxicity burden is as important as ever and these factors 
require attention when redesigning treatment pathways. 
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